Phase I/II study to determine Safety and Pharmacokinetics of subcutaneous administration of potent and broad anti HIV-1 neutralizing monoclonal antibodies (bNAb), given to HIV-1 exposed…
Comments closedAuthor: mblao
The PedMAb protocol has been accepted for publication in the BMC Infectious Diseases under the title: “Safety and pharmacokinetics of subcutaneous administration of broadly neutralizing…
Comments closed
The PedMAb trial is led by MD, Paediatrician and PhD, Gabriella Scarlatti. She is the head of the Viral Evolution and Transmission Unit at I.R.C.C.S.…
Comments closed
Good news: on the 2nd June, the PedMAb 1 trial had recruited a total of 24 baby participants. This means that the recruitment for 3…
Comments closed
The PedMAb consortium held their annual meeting in Durban, South Africa 13-14 April 2023, partly in the same premises as the study: South Africa MRC…
Comments closedDespite considerable progress in reducing HIV-related mortality and increasing the coverage of antiretroviral treatment (ART), HIV continues to be an enormous global health burden in…
Comments closed
Experimental Epidemiology Webinar Series Presented by: The University of Pretoria in collaboration with the South African Medical Research Council and the University of Bergen,Norway. Please…
Leave a Comment